We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+48.43%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.61B
AUM Growth
+$2.03B
Cap. Flow
+$675M
Cap. Flow %
12.03%
Top 10 Hldgs %
60.15%
Holding
73
New
17
Increased
18
Reduced
15
Closed
18

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$124M
2
VERA icon
Vera Therapeutics
VERA
+$100M
3
GRAL
GRAIL Inc
GRAL
+$88.4M
4
ALKS icon
Alkermes
ALKS
+$59.9M
5
SLNO
Soleno Therapeutics
SLNO
+$54.8M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$190M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$159M
3
TERN
Terns Pharmaceuticals
TERN
+$155M
4
ETNB
89bio
ETNB
+$138M
5
GH icon
Guardant Health
GH
+$121M

Sector Composition

Rank Sector Weight
1 Healthcare 78.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLLN
51
BillionToOne Inc
BLLN
$5.8B
$4.09M 0.07%
+50,000
New +$5.07M
RAPT
52
DELISTED
RAPT Therapeutics
RAPT
$3.74M 0.07%
110,448
-640,974
-85% -$19.9M
IVA
53
Inventiva
IVA
$1.05B
$2.28M 0.04%
+490,000
New +$2.28M
JANX icon
54
Janux Therapeutics
JANX
$935M
$1.24M 0.02%
+89,589
New +$2.11M
ANL
55
Adlai Nortye
ANL
$805M
$49.5K ﹤0.01%
+34,852
New +$52.8K
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.25B
– –
-105,085
Closed -$2.24M
AKRO
57
DELISTED
Akero Therapeutics
AKRO
– –
-4,000,978
Closed -$190M
AUTL
58
Autolus Therapeutics
AUTL
$386M
– –
-2,568,613
Closed -$4.19M
JBIO
59
Jade Biosciences
JBIO
$1.22B
– –
-2,279,892
Closed -$19.7M
AVTX icon
60
Avalo Therapeutics
AVTX
$976M
– –
-144,600
Closed -$1.84M
CDTX
61
DELISTED
Cidara Therapeutics
CDTX
– –
-300,000
Closed -$28.7M
ETNB
62
DELISTED
89bio
ETNB
– –
-9,356,171
Closed -$138M
EXAS
63
DELISTED
Exact Sciences
EXAS
– –
-1,000,000
Closed -$54.7M
GHRS icon
64
GH Research
GHRS
$1.87B
– –
-1,250,000
Closed -$17.9M
GMAB icon
65
Genmab
GMAB
$17.7B
– –
-481,267
Closed -$14.8M
IMA
66
ImageneBio Inc
IMA
$63.1M
– –
-878,516
Closed -$7.16M
OLMA icon
67
Olema Pharmaceuticals
OLMA
$1.02B
– –
-3,470,172
Closed -$34M
PEPG icon
68
PepGen
PEPG
$133M
– –
-1,200,000
Closed -$5.54M
PTGX icon
69
Protagonist Therapeutics
PTGX
$8.75B
– –
-1,715,691
Closed -$114M
QURE icon
70
uniQure
QURE
$2.68B
– –
-483,092
Closed -$28.2M
XNCR icon
71
Xencor
XNCR
$1.44B
– –
-549,439
Closed -$6.44M
ZURA icon
72
Zura Bio
ZURA
$497M
– –
-259,014
Closed -$1.12M
CLYM
73
Climb Bio
CLYM
$735M
– –
-509,789
Closed -$1.02M
1 2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
GA
Greenhaven Associates Purchase, New York $6.07B AUM 11.2% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return

Deep Track Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Deep Track Capital held 73 positions worth $5.61B, up 57% from $3.58B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Deep Track Capital deployed $675M of net new capital in Q4 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Vera Therapeutics: 2,821,135 shares worth $143M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $159M trimmed.

  • Deep Track Capital's largest Q4 2025 buy was Vera Therapeutics: 2,821,135 shares worth $143M.
  • Deep Track Capital added most to BioMarin Pharmaceuticals in Q4 2025, an estimated $124M increase.
  • Deep Track Capital's biggest Q4 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $159M.
  • Deep Track Capital fully exited Akero Therapeutics in Q4 2025, selling an estimated $190M.
  • Deep Track Capital's ten largest holdings make up 60% of its $5.61B portfolio in Q4 2025.
  • Deep Track Capital opened 17 new positions and closed 18 in Q4 2025.
  • Deep Track Capital's portfolio value rose 57% quarter-over-quarter to $5.61B.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.